Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cullinan Therapeutics, Inc. - Common Stock (NQ:CGEM)

13.76 +0.11 (+0.81%)
Streaming Delayed Price Updated: 12:22 PM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cullinan Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025
From Cullinan Therapeutics, Inc.; Taiho Pharmaceutical Co., Ltd.; Taiho Oncology, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren’s Disease in the United States
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025
Cullinan and Taiho previously announced the Phase 2b portion of the study met the primary endpoint of overall response rate 
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.